



**Genetic
Signatures**

Transforming
Molecular
Diagnostics



510(k) Filing in Preparation for US Commercial Launch

September 2023



This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written materials/slides for a verbal presentation concerning the Company and should be read in that context. This presentation is proprietary to GSS. It may not be reproduced, disseminated, quoted or referred to, in whole or in part, without express consent of GSS.

No representation or warranty, express or implied, is or will be made in relation to, and no responsibility or liability (whether for negligence, under statute or otherwise) is or will be accepted by the Company or by any of its officers, directors, shareholders, employees or advisers as to or in relation to the accuracy or completeness of the information, statements, opinions or matters (express or implied) arising out of, contained in or derived from this presentation or any omission from this presentation or of any other written or oral information or opinions provided now or in the future to any interested party or its advisers. In particular, no representation or warranty is given as to the achievement or reasonableness of any plans, future projections, management targets, prospects or returns and nothing in this presentation is or should be relied upon as a promise or representation as to the future.

The Company expressly disclaims all liability for any loss or damage of whatsoever kind (whether foreseeable or not) which may arise from any person acting on any information and opinions relating to the Company contained in this presentation or any information which is made available in connection with any further enquiries, notwithstanding any negligence, default or lack of care. In furnishing this presentation, the Company undertakes no obligation to provide any additional information.

Subject to any continuing obligation under applicable law or relevant listing rules of the ASX, the Company disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements in these materials to reflect any change in expectations in relation to any forward-looking statements or any change in events, conditions or circumstances on which any statement is based. Nothing in these materials shall under any circumstances create an implication that there has been no change in the affairs of the Company since the date of the presentation.

This presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dispose of, or issue, or any solicitation of any offer to sell or otherwise dispose of, purchase or subscribe for, any securities, nor does it constitute investment advice, nor shall it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any or contract or investment decision. Without limiting the foregoing, this presentation does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The securities of Genetic Signatures have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or sold in the United States except in compliance with the registration requirements of the Securities Act and any other applicable securities laws or pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws.

The receipt of this presentation by any person and any information contained herein or subsequently communicated to any person is not to be taken as constituting the giving of investment advice by the Company or any other person to any such person. No such person should expect the Company or any of its officers, directors, shareholders, employees or advisers to owe it any duties or responsibilities and should take its own professional advice. The Recipient must rely solely on its own knowledge, investigation, judgement and assessment of the matters which are the subject of this presentation and to satisfy itself as to the accuracy and completeness



- **Proprietary 3base® technology platform** - a revolutionary approach to molecular diagnostic assays for infectious diseases
- **Dramatically simplifies multiple pathogen testing** from a single sample (multiplexing); more informative—simpler with fewer reagents
- **Strong commercial adoption** in AU market – expanding into EU & US
 - 4 diagnostic test kit groups cleared & commercially launched
 - 5 new kits completing development
 - Expanding network of channel partners in EMEA
 - Strong underlying growth in core revenue streams
 - FY23 sales of \$16.9M with 75% from syndromic testing products
- **US commercial launch** underway with first product submitted to FDA
 - Gastrointestinal Parasite Detection kit, addresses unmet need
 - 5.5 million traditional tests conducted in the US per annum
 - Engagement started with pre-qualified customer experience sites to begin evaluating the product workflow
 - These sites are expected to become initial customers once the kit is cleared for sale





Financial information

| | |
|------------------------------|----------|
| Share price (1-September-23) | A\$0.445 |
| Shares on issue | 143.4m |

Market capitalisation **A\$63.8m**

Cash (30-Jun-23) A\$16.3m

Debt (30-Jun-23) Nil

Enterprise value **A\$47.5m**

Top shareholders %


Asia Union
(Chris Abbott private investment) 26.2%

Perennial Value Management 15.0%

Fidelity International 6.9%

Directors & management 3.0%





* Human Papilloma virus sequences

- **Molecular diagnostic tests are based on DNA/RNA sequences**

- DNA/RNA is unique to each organism

- **Genetic Signatures 3base® makes multiplex testing easier:**

- **More informative** – detect related pathogens/genes using fewer tests
- **Simpler** – fewer reagents with better matched, reaction conditions

3base® conversion does not impact sensitivity or specificity and does not require any extra user steps





- **Syndromic testing:** simultaneously test for multiple pathogens that all can cause the same signs and symptoms
 - **Respiratory infections:** cough, runny nose, sore throat, headache
 - **Gastrointestinal infections:** nausea, diarrhea, vomiting, cramps, fever
- **Syndromic testing**
 - Allows single test to determine the potential cause of a disorder
 - Avoids having to order separate tests for each possible pathogen
- **Genetic Signatures' *EasyScreen™* is ideal for syndromic testing**
 - Tests for over 100 different types of pathogens
 - Able to detect variants (i.e. different strains or subtypes)
 - Combine tests to create *EasyScreen™* Syndromic Detection Test Kits
 - Detect >20 different pathogens from a single sample
- **Millions of 3base® *Easyscreen™* tests have been performed**





Sales Revenue (A\$m)



FY23 sales \$16.9 million

- Anticipated material decline in pathogen-specific molecular testing for SARS-CoV-2 experienced across the industry
- Replaced with growing syndromic respiratory sales—long-term, durable market
- Several Covid only customers currently trialing or commenced purchase of *EasyScreen™* kits for other indications
- Non-Covid only sales up 38% in FY23 and account for 75% of sales in FY23
- 9% sales to international customers—set to grow with increased EU presence and as products cleared in US

Maintain successful strategy of targeting focus towards high-volume customer groups

- High-throughput labs
- Multi-hospital groups
- Private pathology chains
- Government-led programs



| A\$'000s | FY23 | FY22 |
|------------------------------------|-----------------|---------------|
| Sales revenue | 16,939 | 35,421 |
| Cost of materials & freight | (7,996) | (11,989) |
| Gross profit | 8,943 | 23,432 |
| Employee benefits expense | (15,037) | (11,948) |
| Scientific consumables & clinical | (5,119) | (3,133) |
| Other expenses | (6,429) | (3,889) |
| EBITDA | (17,642) | 4,462 |
| Depreciation & amortisation | (1,526) | (1,616) |
| EBIT | (19,168) | 2,846 |
| Other income | 5,116 | 217 |
| (Loss)/profit before tax | (14,052) | 3,063 |
| Income tax | - | - |
| Net (loss)/income | (14,052) | 3,063 |
| | | |
| Net cash inflows/(outflows) | (20,548) | 6,776 |
| Cash balance (30 June) | 16,349 | 36,897 |


Reduced SARS-CoV-2 molecular testing replaced with growing syndromic respiratory sales:

- Sales revenue of \$16.9 million compared to \$35.4 million in FY22;
- Non-COVID-19 only sales up 38% in FY23 and account for 75% of sales in FY23
- Gross margin on materials 60% compared to 70% p.c.p. primarily attributable to provision for obsolescence during the year
- R&D Tax Incentive receivable of \$6.9m expected based on increase in eligible expenditure during the year

Substantial investments made in FY23 in growth opportunities funded from existing cash and anticipated future cash flows:

- International markets; new products; regulatory clearances; product launches; internal capabilities (clinical, regulatory); technology improvements; sample-to-result instrument.

Robust pipeline with multiple products cleared for sale





Launching into Worlds Largest Molecular Diagnostic Market






| Protozoan Pathogen | Symptoms | Antibiotic |
|-------------------------------------|--|--|
| <i>Giardia lamblia/intestinalis</i> | <p>Common set of symptoms from all gastric protozoan infections which include:</p> <ul style="list-style-type: none"> • Abdominal pain • Diarrhea • Greasy stools • Nausea or vomiting • Gas or bloating • Dysentery • Fatigue • Weight loss | Metronizadole, tinidazole, nitazoxanide |
| <i>Cryptosporidium spp.</i> | | Nitazoxanide (some patients) |
| <i>Entamoeba histolytica</i> | | Metronizadole, tinidazole |
| <i>Cyclospora cayetanensis</i> | | Trimethoprim-sulfmethoxazole |
| <i>Enterocytozoon bieneusi</i> | | Nitaoxanide (no established guidelines) |
| <i>Encephalitozoon intestinalis</i> | | Albendazole |
| <i>Dientamoeba fragilis</i> | | Lodoquinol (US), secnidazole, ornidazole |
| <i>Blastocystis hominis</i> | | Metronizadole, tinidazole, |

- **3base®** simplifies the conditions for multiplexing several pathogen tests into a single tube
- **3base®** enables the detection of different strains and variants of pathogens within the same test


Current testing protocols are complex and inefficient

510(k) Filing
September 2023




This complex inefficient process has been replaced by a streamlined molecular assay

Note: in outbreak scenarios with a known organism, consider ordering a specific test for that organism. (CYCL/Cyclospora Stain, Feces; CRYP / Cryptosporidium Antigen, Feces; GIAR / Giardia Antigen, Feces; bacterial stool culture).



- **United States has a significant commercial opportunity for testing for gastrointestinal parasites**
 - 5.5 million tests conducted in the US per annum
 - Primarily culture/microscopy: slow, labour intensive, unreliable
 - Detects leading clinically significant protozoan infections
- ***EasyScreen*TM Gastrointestinal Parasite Detection Kit fills an unmet need**
 - Syndromic, molecular solution provides a more sensitive, rapid, and broad detection for 8 leading gastrointestinal parasites
 - A number of targets are unique for GSS' solution
 - Results in hours instead of days or weeks, seen with traditional diagnostics
- **510(k) submitted with US FDA in September 2023**



Rapid simultaneous testing for range of pathogens that cause a similar set of symptoms in presenting patients



Higher sensitivity and specificity



Able to combine multiple targets into single assay




Workflow automation



Quicker turnaround times

* O&P = Ova (egg) and parasite testing using culture and microscopy



"Once ordering physicians have used molecular for parasite screening, they become users. They are not going back to O&P"*

Professor Marc R. Couturier
Medical Director, ARUP Laboratories



EasyScreen[™] Gastrointestinal Parasite Detection Kit

Underpinned by patented
3base[®] technology





*“Molecular is going to impact patient management in three ways. Your results will come back quicker, they will potentially be more accurate, and they will also help **redirect the evolving differential diagnosis by providing both positive and negative results with accuracy and efficiency.**”*

Dr Glen Hansen

Medical Director, Hennipin Country Medical Center (now Chief Medical Officer at Seegene (US))

*“One of the things I really liked about the EasyScreen™ method was the range of targets that it can detect. I’ve seen a lot of other molecular testing that has a narrower range of targets. So **the fact that this one has eight was wonderful to me.**”*

Lexi Bracken

Research Scientist, ARUP Laboratories



*Since using Genetic Signatures’ molecular panel for GI infections, I am able to **rationalize and streamline our workflow. That allows for significant staff savings and cost savings.** The only reason we would do microscopy now is if it’s a specific request for something that is not on the molecular panel”*

Principal Hospital Scientist, Australia



● Focused prospects


- Targeting the top 30-50 mid to high throughput laboratories in the US
- 80/20 rule with majority of tests conducted by 20% of sites
- Allows direct sales effort

● Direct sales model

- Highly experienced sales team represented across the country
 - Actively developing customer relationships and the sales pipeline
- Also supported by a team of technical and clinical operations experts in the region, and from HQ in Australia

● US infrastructure established

- Distribution and warehouse facility in California
- Working laboratory which houses instrumentation and enables R&D capabilities, and training support for the local market




Participating laboratories in The National Respiratory and Enteric Virus Surveillance System (NREVSS). Source: CDC



Laboratory facility at BioLabs at the Lundquist Institute, California, United States



US team representation at ASM Microbe 2023 conference in Houston, Texas.



● US market preparation activities underway


- Delivery of an educational webinar series and white paper involving industry parasitology experts with global reach
- US focus group executed with key opinion leaders to deep dive into product appeal and positioning
- Sales and marketing presence at leading international conferences in US

● A select, limited number of pre-qualified customer experience sites in the US can now evaluate the *EasyScreen™* Gastrointestinal Parasite Detection Kit

- Establish the **3base®** technology in their laboratories
- Demonstrate the benefits of employing the **3base®** molecular syndromic testing for gastrointestinal protozoan infections



- **Commercial sales expected to start soon after FDA clearance**
 - Positive forward indicators with many customer experience sites expected to transition to a purchasing customer
 - Solid opportunity pipeline supported by sales and marketing efforts in preparation of FDA clearance
 - Aiming for 40% market share of ~5.5 million tests / year
- **Product diversification for future 3base® products to follow**
 - Regulatory dossier relevant for other *EasyScreen™* products



Entamoeba parasite



Global Growth





- **Recent Key appointments**
 - Distributor Channel Manager – Europe
 - Regulatory Affairs and Quality Assurance Manager – Europe
 - Head of Clinical Operations – North America
- **New channel partners appointed**
 - Europe, Israel & Middle East
- **Industry meetings with solid brand exposure**
 - Europe – ECCMID and others
 - USA – ASM and others
- **Customer trials**
 - Local and international customer sites trialing other *EasyScreen™* gastrointestinal & respiratory detection kits for adoption





- **Leverage experience in AU market to grow international sales**
 - Europe – drive adoption of other **3base®** products
 - US – build **3base®** franchise once the Gastrointestinal Parasite Detection Kit is cleared
- **Build & expand portfolio of *EasyScreen™* products**
 - Expand menu of **3base®** tests
 - Develop new *EasyScreen™* syndromic detection kits
 - Secure registration for new *EasyScreen™* products
- **Embed 3base® technology in high-value customer's workflow**
 - Increase adoption of *EasyScreen™* kits for more applications
 - Broader range of commercial arrangements with customers
- **Next Generation, “sample-to-answer” Instrument**





● Next Generation, “sample-to-answer” Instrument

- Highly automated, little hands-on time
- High-throughput
- Same testing parameters for all panels – **3base®**
- Can run multiple products in a single run
 - Highly flexible
- Can run mixed specimen types in a single run
- Embed use of **3base®** with customers



Images are concepts only





- **US *EasyScreen*™ Gastrointestinal Parasite Detection Kit**
 - 510(k) clearance
 - Launch product once clearance is granted
- **Increase sales and presence in UK and EMEA markets**
 - Contracts with new customers
 - Direct sales force and distributor appointments
 - Expansion of BioHub laboratory in Birmingham, UK
- **Complete US clinical trial for next *EasyScreen*™ product**
 - Syndromic detection kit for common respiratory infections
 - Targeting a 510(k) submission for *EasyScreen*™ Essentials Respiratory Detection Kit
- **R&D initiatives for new products**
 - New *EasyScreen*™ detection kits
 - Technology and workflow improvements
 - Development of Next Generation Instrument prototype





Contact Us

Dr John Melki

Managing Director & Chief Executive Officer

E: john.melki@geneticsignatures.com

P: +61 (0)2 9870 7580

Karl Pechmann

Chief Financial & Operating Officer &
Company Secretary

E: karl.pechmann@geneticsignatures.com

Visit us

www.geneticsignatures.com

Follow us

